CN102215858A - 使用单剂量奥利万星的治疗方法 - Google Patents

使用单剂量奥利万星的治疗方法 Download PDF

Info

Publication number
CN102215858A
CN102215858A CN2009801439475A CN200980143947A CN102215858A CN 102215858 A CN102215858 A CN 102215858A CN 2009801439475 A CN2009801439475 A CN 2009801439475A CN 200980143947 A CN200980143947 A CN 200980143947A CN 102215858 A CN102215858 A CN 102215858A
Authority
CN
China
Prior art keywords
oritavancin
pharmaceutically acceptable
dose
acceptable salt
potion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801439475A
Other languages
English (en)
Chinese (zh)
Inventor
D·勒霍瓦
T·R·帕
G·梅克
P·艾蒂安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicines Co
Original Assignee
Targanta Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102215858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targanta Therapeutics Corp filed Critical Targanta Therapeutics Corp
Priority to CN201610900690.5A priority Critical patent/CN106620649A/zh
Publication of CN102215858A publication Critical patent/CN102215858A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2009801439475A 2008-08-30 2009-08-29 使用单剂量奥利万星的治疗方法 Pending CN102215858A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610900690.5A CN106620649A (zh) 2008-08-30 2009-08-29 使用单剂量奥利万星的治疗方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9331408P 2008-08-30 2008-08-30
US61/093314 2008-08-30
US9349708P 2008-09-02 2008-09-02
US61/093497 2008-09-02
PCT/US2009/055466 WO2010025438A2 (en) 2008-08-30 2009-08-29 Methods of treatment using single doses of oritavancin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610900690.5A Division CN106620649A (zh) 2008-08-30 2009-08-29 使用单剂量奥利万星的治疗方法

Publications (1)

Publication Number Publication Date
CN102215858A true CN102215858A (zh) 2011-10-12

Family

ID=41722337

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801439475A Pending CN102215858A (zh) 2008-08-30 2009-08-29 使用单剂量奥利万星的治疗方法
CN201610900690.5A Pending CN106620649A (zh) 2008-08-30 2009-08-29 使用单剂量奥利万星的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610900690.5A Pending CN106620649A (zh) 2008-08-30 2009-08-29 使用单剂量奥利万星的治疗方法

Country Status (18)

Country Link
US (2) US8420592B2 (enExample)
EP (3) EP3006038B1 (enExample)
JP (1) JP5782615B2 (enExample)
CN (2) CN102215858A (enExample)
AU (1) AU2009285564B2 (enExample)
CA (1) CA2736860C (enExample)
DK (2) DK2337575T3 (enExample)
EA (1) EA020490B1 (enExample)
ES (2) ES2570401T3 (enExample)
FI (1) FI3006038T3 (enExample)
HU (3) HUE027373T2 (enExample)
MX (1) MX2011002249A (enExample)
NL (1) NL300834I2 (enExample)
NO (1) NO2016019I2 (enExample)
NZ (1) NZ591525A (enExample)
PL (2) PL2337575T3 (enExample)
PT (1) PT3006038T (enExample)
WO (1) WO2010025438A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573882A (zh) * 2009-04-28 2012-07-11 塔尔甘塔治疗公司 用奥利万星治疗细菌感染的方法
CN107206050A (zh) * 2014-07-17 2017-09-26 医药公司 高纯度奥利万星及其生产方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027373T2 (hu) * 2008-08-30 2016-09-28 The Medicines Co Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával
WO2014031681A1 (en) * 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
US20160101148A1 (en) * 2013-04-22 2016-04-14 The Medicines Company Treatment and prevention of bacterial skin infections using oritavancin
US20160206688A1 (en) * 2013-08-26 2016-07-21 The Medicines Company Methods for treating bacteremia and osteomyelitis using oritavancin
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
WO2015192031A1 (en) * 2014-06-12 2015-12-17 Cem-102 Pharmaceuticals, Inc. Compositions and methods for treating bone and joint infections
KR20180111948A (ko) * 2016-02-18 2018-10-11 멜린타 테라퓨틱스, 인크. 오리타반신 제제
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5994297A (en) * 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
DE60016734T2 (de) * 1999-05-03 2005-12-08 Eli Lilly And Co., Indianapolis Monatliche gaben von glykopeptid-antibiotika zur langzeitprävention von streptokokkus pneumoniae infektionen
ES2316445T3 (es) 2000-05-02 2009-04-16 Theravance, Inc. Composicion que contiene una ciclodextrina y un antibiotico glicopeptidico.
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
CN1662643A (zh) * 2002-05-28 2005-08-31 贝克顿·迪金森公司 人腺泡细胞的扩增和转分化
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US9089507B2 (en) * 2006-09-25 2015-07-28 The Medicines Company Use of oritavancin for prevention and treatment of anthrax
HUE027373T2 (hu) * 2008-08-30 2016-09-28 The Medicines Co Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C.M.RUBINO等: "Use of pharmacokinetic-pharmacodynamic principles for decision support for short-course oritavancin dosing regimens for complicated skin and skin structure infections", 《PHARMACOKINETICS AND PHARMACODYNAMICS》 *
GERALD J. FETTERLY ET AL.: "Pharmacokinetics of Oritavancin in Plasma and Skin Blister Fluid following Administration of a 200-Milligram Dose for 3 Days or a Single 800-Milligram Dose", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
RONALD N. JONES ET AL.: "In vitro activity and spectrum of LY333328, a novel glycopeptide derivative", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *
谭玲等: "新型糖肽类抗生素奥利万星", 《中国新药杂志》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573882A (zh) * 2009-04-28 2012-07-11 塔尔甘塔治疗公司 用奥利万星治疗细菌感染的方法
CN107206050A (zh) * 2014-07-17 2017-09-26 医药公司 高纯度奥利万星及其生产方法

Also Published As

Publication number Publication date
EA020490B1 (ru) 2014-11-28
NL300834I2 (enExample) 2016-11-16
EP2337575B1 (en) 2016-04-13
MX2011002249A (es) 2011-06-24
AU2009285564B2 (en) 2014-05-22
HUE027373T2 (hu) 2016-09-28
US8420592B2 (en) 2013-04-16
PL3006038T3 (pl) 2024-11-12
US20130172237A1 (en) 2013-07-04
CN106620649A (zh) 2017-05-10
US20110201546A1 (en) 2011-08-18
WO2010025438A9 (en) 2010-05-14
DK3006038T3 (da) 2024-08-26
JP2012501349A (ja) 2012-01-19
CA2736860A1 (en) 2010-03-04
DK2337575T3 (en) 2016-05-23
CA2736860C (en) 2020-04-28
WO2010025438A2 (en) 2010-03-04
EP3006038B1 (en) 2024-07-03
EA201100413A1 (ru) 2012-01-30
AU2009285564A1 (en) 2010-03-04
ES2994966T3 (en) 2025-02-04
NZ591525A (en) 2014-03-28
EP2337575A4 (en) 2012-10-17
EP3006038A1 (en) 2016-04-13
EP2337575A1 (en) 2011-06-29
FI3006038T3 (fi) 2024-08-12
HUS1600039I1 (hu) 2016-11-28
EP4464375A2 (en) 2024-11-20
NO2016019I2 (no) 2019-01-25
PL2337575T3 (pl) 2016-09-30
ES2570401T3 (es) 2016-05-18
JP5782615B2 (ja) 2015-09-24
EP4464375A3 (en) 2025-02-26
NO2016019I1 (no) 2016-10-11
HUE068423T2 (hu) 2024-12-28
PT3006038T (pt) 2024-08-23

Similar Documents

Publication Publication Date Title
JP5782615B2 (ja) オリタバンシンの単回用量を用いる治療の方法
JP5591112B2 (ja) オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法
JP5469511B2 (ja) 微生物の院内感染症の治療用医薬の製造におけるタウロリジンまたはタウラルタムのような抗微生物薬剤の使用
WO2011008193A1 (en) Fusidic acid dosing regimens for treatment of bacterial infections
AU2017259960A1 (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (UTI) treatment
US8450300B2 (en) Fusidic acid dosing regimens for treatment of bacterial infections
ES2981472T3 (es) Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina
US20190388417A1 (en) Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity
EA016803B1 (ru) Лечение инфекционных заболеваний
US20160101148A1 (en) Treatment and prevention of bacterial skin infections using oritavancin
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
EP3038615A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
ES2949169T3 (es) Procedimientos para tratar la bacteriemia y la osteomielitis utilizando oritavancina

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: MEDICINES CORP.

Free format text: FORMER OWNER: TARGANTA THERAPEUTICS CORP.

Effective date: 20130912

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130912

Address after: new jersey

Applicant after: The Medicines Company

Address before: Massachusetts, USA

Applicant before: Targanta Therapeutics Corp.

RJ01 Rejection of invention patent application after publication

Application publication date: 20111012

RJ01 Rejection of invention patent application after publication